Clinical applications of advanced lipoprotein testing in diabetes mellitus

Bibliography

• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5), 1047–1053 (2004)
   Google Scholar
• Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993. Diabetes Care 21(7), 1138–1145 (1998)
   Google Scholar
• Merz CN, Buse JB, Tuncer D, Twillman GB. Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. J. Am. Coll. Cardiol. 40(10), 1877–1881 (2002)
   Google Scholar
• Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44(Suppl. 2), S14–S21 (2001)
   Google Scholar
• Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100(10), 1134–1146 (1999)
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2011. Diabetes Care 29(Suppl. 1), S4–S42 (2011)
   Google Scholar
• Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285(19), 2486–2497 (2001)
   Google Scholar
• Fox CS, Coady S, Sorlie PD et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 115(12), 1544–1550 (2007)
   Google Scholar
• Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114(6), 597–605 (2011)
   Google Scholar
• Lossow WJ, Lindgren FT, Murchio JC, Stevens GR, Jensen LC. Particle size and protein content of six fractions of the Sf 20 plasma lipoproteins isolated by density gradient centrifugation. J. Lipid Res. 10(1), 68–76 (1969)
   Google Scholar
• Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J. Lipid Res. 23(1), 97–104 (1982)
   Google Scholar
• Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin. Chem. 38(9), 1632–1638 (1992)
   Google Scholar
• Ip S, Lichtenstein AH, Chung M, Lau J, Balk EM. Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes. Ann. Intern. Med. 150(7), 474–484 (2011)
   Google Scholar
• Chung M, Lichtenstein AH, Ip S, Lau J, Balk EM. Comparability of methods for LDL subfraction determination: a systematic review. Atherosclerosis 205(2), 342–348 (2011)
   Google Scholar
• Rosenson RS, Brewer HB Jr, Chapman MJ et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin. Chem. 57(3), 392–410 (2011)
   Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143–3421 (2002)
   Google Scholar
• Cui Y, Blumenthal RS, Flaws JA et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch. Intern. Med. 161(11), 1413–1419 (2001)
   Google Scholar
• Arsenault BJ, Rana JS, Stroes ES et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J. Am. Coll. Cardiol. 55(1), 35–41 (2011)
   Google Scholar
• Brook RD, Kansal M, Bard RL, Eagle K, Rubenfire M. Usefulness of low-density lipoprotein particle size measurement in cardiovascular disease prevention. Clin. Cardiol. 28(11), 534–537 (2005)
   Google Scholar
• Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112(22), 3375–3383 (2005)
   Google Scholar
• Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82(2), 495–506 (1990)
   Google Scholar
• Lamarche B, Tchernof A, Moorjani S et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 95(1), 69–75 (1997)
   Google Scholar
• Griffin BA, Skinner ER, Maughan RJ. Plasma high density lipoprotein subfractions in subjects with different coronary risk indices as assessed by plasma lipoprotein concentrations. Atherosclerosis 70(1–2), 165–169 (1988)
   Google Scholar
• Cheung MC, Brown BG, Wolf AC, Albers JJ. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J. Lipid Res. 32(3), 383–394 (1991)
   Google Scholar
• Kontush A, Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23(10), 1881–1888 (2003)
   Google Scholar
• Goldberg IJ. Clinical review 124: Diabetic dyslipidemia: causes and consequences. J. Clin. Endocrinol. Metab. 86(3), 965–971 (2001)
   Google Scholar
• Siegel RD, Cupples A, Schaefer EJ, Wilson PW. Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study. Metabolism 45(10), 1267–1272 (1996)
   Google Scholar
• Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler. Thromb. 12(12), 1496–1502 (1992)
   Google Scholar
• Tan CE, Chew LS, Chio LF et al. Cardiovascular risk factors and LDL subfraction profile in Type 2 diabetes mellitus subjects with good glycaemic control. Diabetes Res. Clin. Pract. 51(2), 107–114 (2001)
   Google Scholar
• Haffner SM, Mykkanen L, Stern MP, Paidi M, Howard BV. Greater effect of diabetes on LDL size in women than in men. Diabetes Care 17(10), 1164–1171 (1994)
   Google Scholar
• Friedlander Y, Kidron M, Caslake M, Lamb T, Mcconnell M, Bar-On H. Low density lipoprotein particle size and risk factors of insulin resistance syndrome. Atherosclerosis 148(1), 141–149 (2000)
   Google Scholar
• Selby JV, Austin MA, Newman B et al. LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation 88(2), 381–387 (1993)
   Google Scholar
• Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am. J. Cardiol. 81(4A), 18B–25B (1998)
   Google Scholar
• Drexel H, Aczel S, Marte T, Vonbank A, Saely CH. Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis. Atherosclerosis 208(2), 484–489 (2010).
   Google Scholar
• Demonstrates similar changes in the lipid profile of those with prediabetes compared to those with overt diabetes mellitus.
   Google Scholar
• Berneis K, Jeanneret C, Muser J, Felix B, Miserez AR. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in Type 2 diabetes. Metabolism 54(2), 227–234 (2005)
   Google Scholar
• Syvanne M, Ahola M, Lahdenpera S et al. High density lipoprotein subfractions in non-insulin-dependent diabetes mellitus and coronary artery disease. J. Lipid Res. 36(3), 573–582 (1995)
   Google Scholar
• Williams PT, Krauss RM, Vranizan KM, Stefanick ML, Wood PD, Lindgren FT: Associations of lipoproteins and apolipoproteins with gradient gel electrophoresis estimates of high density lipoprotein subfractions in men and women. Arterioscler. Thromb. 12(3), 332–340 (1992)
   Google Scholar
• Stefanovic A, Kotur-Stevuljevic J, Spasic S et al. HDL 2 particles are associated with hyperglycaemia, lower PON1 activity and oxidative stress in Type 2 diabetes mellitus patients. Clin. Biochem. 43(15), 1230–1235 (2010).
   Google Scholar
• Demonstrates that the prevalence of diabetes mellitus and the metabolic syndrome was higher among those with discordant phenotypes. In these patients, LDL-P is a more reliable predictor of cardiovascular events.
   Google Scholar
• Festa A, Williams K, Hanley AJ et al. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation 111(25), 3465–3472 (2005).
   Google Scholar
• Shows similar changes in the lipid profile of those with prediabetes compared to those with overt diabetes mellitus.
   Google Scholar
• Austin MA, Mykkanen L, Kuusisto J et al. Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation 92(7), 1770–1778 (1995)
   Google Scholar
• Hodge AM, Jenkins AJ, English DR, O'dea K, Giles GG. NMR-determined lipoprotein subclass profile predicts Type 2 diabetes. Diabetes Res. Clin. Pract. 83(1), 132–139 (2011)
   Google Scholar
• Lu J, Jiang W, Yang JH et al. Electronegative LDL impairs vascular endothelial cell integrity in diabetes by disrupting fibroblast growth factor 2 (FGF2) autoregulation. Diabetes 57(1), 158–166 (2008)
   Google Scholar
• Chen CH, Jiang T, Yang JH et al. Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation 107(16), 2102–2108 (2003).νν Reports significant differences in lipid subfractions in data extracted from the Framingham Heart Study in the metabolic syndrome.
   Google Scholar
• Mcneill KL, Fontana L, Russell-Jones DL, Rajman I, Ritter JM, Chowienczyk PJ. Inhibitory effects of low-density lipoproteins from men with type II diabetes on endothelium-dependent relaxation. J. Am. Coll. Cardiol. 35(6), 1622–1627 (2000)
   Google Scholar
• Skyrme-Jones RA, O'brien RC, Luo M, Meredith IT. Endothelial vasodilator function is related to low-density lipoprotein particle size and low-density lipoprotein vitamin E content in Type 1 diabetes. J. Am. Coll. Cardiol. 35(2), 292–299 (2000)
   Google Scholar
• Kathiresan S, Otvos JD, Sullivan LM et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 113(1), 20–29 (2011).
   Google Scholar
• Reports significant differences in lipid subfractions in data extracted from the Framingham Heart Study in the metabolic syndrome.
   Google Scholar
• Gazi I, Tsimihodimos V, Filippatos T, Bairaktari E, Tselepis AD, Elisaf M. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism 55(7), 885–891 (2011)
   Google Scholar
• Rizzo M, Pernice V, Frasheri A et al. Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome. Clin Endocrinol. (Oxf.) 70(6), 870–875 (2011)
   Google Scholar
• Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among u.s. adults. Diabetes Care 27(10), 2444–2449 (2004)
   Google Scholar
• Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J. Clin. Lipidol. 5(2), 105–113 (2011).
   Google Scholar
• Demonstrates that the prevalence of diabetes mellitus and the metabolic syndrome was higher among those with discordant phenotypes. In these patients, LDL-P is a more reliable predictor of cardiovascular events.
   Google Scholar
• Halle M, Berg A, Garwers U et al. Influence of 4 weeks' intervention by exercise and diet on low-density lipoprotein subfractions in obese men with Type 2 diabetes. Metabolism 48(5), 641–644 (1999)
   Google Scholar
• Wagner AM, Jorba O, Rigla M et al. Effect of improving glycemic control on low-density lipoprotein particle size in Type 2 diabetes. Metabolism 52(12), 1576–1578 (2003)
   Google Scholar
• Caixas A, Ordonez-Llanos J, De Leiva A, Payes A, Homs R, Perez A. Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients. Diabetes 46(7), 1207–1213 (1997)
   Google Scholar
• Rivellese AA, Patti L, Romano G et al. Effect of insulin and sulfonylurea therapy, at the same level of blood glucose control, on low density lipoprotein subfractions in Type 2 diabetic patients. J. Clin. Endocrinol. Metab. 85(11), 4188–4192 (2000)
   Google Scholar
• Ohira M, Miyashita Y, Ebisuno M et al. Effect of metformin on serum lipoprotein lipase mass levels and LDL particle size in Type 2 diabetes mellitus patients. Diabetes Res. Clin. Pract. 78(1), 34–41 (2007).
   Google Scholar
• Indicates that metformin therapy leads to favorable changes in lipid subfractions independent of improved glycemic control.
   Google Scholar
• Bavirti S, Ghanaat F, Tayek JA. Peroxisome proliferator-activated receptor-gamma agonist increases both low-density lipoprotein cholesterol particle size and small high-density lipoprotein cholesterol in patients with Type 2 diabetes independent of diabetic control. Endocr. Pract. 9(6), 487–493 (2003)
   Google Scholar
• Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JP. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early Type 2 diabetes. Diabetes Care 27(1), 41–46 (2004)
   Google Scholar
• Nakano K, Hasegawa G, Fukui M et al. Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with Type 2 diabetes. Endocr. J. 57(5), 423–430 (2010)
   Google Scholar
• Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes and dyslipidemia. Diabetes Care 28(7), 1547–1554 (2005)
   Google Scholar
• Deeg MA, Buse JB, Goldberg RB et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with Type 2 diabetes and dyslipidemia. Diabetes Care 30(10), 2458–2464 (2007).
   Google Scholar
• Demonstrates that pioglitazone has a larger effect on improving lipid subfractions in patients compared to rosiglitazone therapy in a large randomized trial.
   Google Scholar
• Berneis K, Rizzo M, Stettler C et al. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes. Expert Opin. Pharmacother. 9(3), 343–349 (2008)
   Google Scholar
• Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with Type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care 33(8), 1759–1765 (2010)
   Google Scholar
• Hsieh J, Longuet C, Baker CL et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 53(3), 552–561 (2010)
   Google Scholar
• Soedamah-Muthu SS, Colhoun HM, Thomason MJ et al. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in Type 2 diabetic patients with ischaemic heart disease. Atherosclerosis 167(2), 243–255 (2003)
   Google Scholar
• Charlton-Menys V, Betteridge DJ, Colhoun H et al. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clin. Chem. 55(3), 473–480 (2011)
   Google Scholar
• Kappelle PJ, Dallinga-Thie GM, Dullaart RP. Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in Type 2 diabetes mellitus: relevance for non-HDL cholesterol and apolipoprotein B guideline targets. Biochim. Biophys. Acta 1801(1), 89–94 (2010)
   Google Scholar
• Lee SJ, Sacks FM. Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus. Am. J. Cardiol. 92(2), 121–124 (2003)
   Google Scholar
• Rosenson R. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis 185(2), 327–330 (2011)
   Google Scholar
• Rosenson RS, Abby SL, Jones MR. Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with Type 2 diabetes. Atherosclerosis 204(2), 342–344 (2011)
   Google Scholar
• Berneis K, Rizzo M, Berthold HK, Spinas GA, Krone W, Gouni-Berthold I. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Eur. Heart J. 31(13), 1633–1639 (2010)
   Google Scholar
• Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Clin. Ther. 29(11), 2419–2432 (2007)
   Google Scholar
• Nakou ES, Filippatos TD, Agouridis AP, Kostara C, Bairaktari ET, Elisaf MS. The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients. Lipids 45(5), 445–450 (2010).
   Google Scholar
• Demonstrates particular benefits in HDL subfractions in patients with diabetes mellitus with niacin therapy and is of interest.
   Google Scholar
• Vakkilainen J, Steiner G, Ansquer JC et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107(13), 1733–1737 (2003)
   Google Scholar
• Mostad IL, Bjerve KS, Lydersen S, Grill V. Effects of marine n-3 fatty acid supplementation on lipoprotein subclasses measured by nuclear magnetic resonance in subjects with Type II diabetes. Eur. J. Clin. Nutr. 62(3), 419–429 (2008)
   Google Scholar
• Patti L, Maffettone A, Iovine C et al. Long-term effects of fish oil on lipoprotein subfractions and low density lipoprotein size in non-insulin-dependent diabetic patients with hypertriglyceridemia. Atherosclerosis 146(2), 361–367 (1999)
   Google Scholar
• Baumstark MW, Frey I, Berg A, Keul J. Influence of n-3 fatty acids from fish oils on concentration of high- and low-density lipoprotein subfractions and their lipid and apolipoprotein composition. Clin. Biochem. 25(5), 338–340 (1992)
   Google Scholar
• Mckenney JM, McCormick LS, Schaefer EJ, Black DM, Watkins ML. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am. J. Cardiol. 88(3), 270–274 (2001)
   Google Scholar
• Kuvin JT, Dave DM, Sliney KA et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am. J. Cardiol. 98(6), 743–745 (2011)
   Google Scholar
• Pan J, Lin M, Kesala RL, Van J, Charles MA. Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes. Diabetes Obes. Metab. 4(4), 255–261 (2002).
   Google Scholar
• Demonstrates particular benefits in HDL subfractions in patients with diabetes mellitus with niacin therapy.
   Google Scholar
• Lai E, De Lepeleire I, Crumley TM et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin. Pharmacol. Ther. 81(6), 849–857 (2007)
   Google Scholar
• Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361(9374), 2005–2016 (2003)
   Google Scholar
• Chung BH, Segrest JP, Ray MJ et al. Single vertical spin density gradient ultracentrifugation. Methods Enzymol. 128, 181–209 (1986)
   Google Scholar
• Warnick GR, Mcnamara JR, Boggess CN, Clendenen F, Williams PT, Landolt CC. Polyacrylamide gradient gel electrophoresis of lipoprotein subclasses. Clin. Lab. Med. 26(4), 803–846 (2011)
   Google Scholar
• Garvey WT, Kwon S, Zheng D et al. Effects of insulin resistance and Type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52(2), 453–462 (2003).
   Google Scholar